Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

43.53USD
20 Jun 2017
Change (% chg)

$-0.15 (-0.34%)
Prev Close
$43.68
Open
$43.37
Day's High
$43.59
Day's Low
$43.33
Volume
90,552
Avg. Vol
485,356
52-wk High
$57.40
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $86,853.49
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.67
Yield (%): 3.02

Financials

  NVO.N Industry Sector
P/E (TTM): 19.35 13.63 17.39
EPS (TTM): 2.31 -- --
ROI: 89.20 -6.95 -5.22
ROE: 99.57 -6.42 -4.48

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

COPENHAGEN Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

24 Jun 2017

Novo Nordisk says obesity drug helps up to 13.8 pct weight loss in phase 2 trial

COPENHAGEN, June 23 Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

24 Jun 2017

CORRECTED-BRIEF-Novo Nordisk submits EU application for Tresiba label update

* Submits application in the EU for including data from the DEVOTE trial in the Tresiba label Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)

14 Jun 2017

BRIEF-Novo Nordisk says Tresiba showed significant reduction in rates of severe hypoglycaemia compared to insulin glargine

* tresiba showed no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine

13 Jun 2017

Novo Nordisk reveals results from real-world study of Tresiba drug

COPENHAGEN, June 10 Danish diabetes drugmaker Novo Nordisk on Saturday presented its findings from the real-world study EU-TREAT at the American Diabetes Association's 77th Scientific Sessions.

10 Jun 2017

BRIEF-Novo Nordisk gets EU approval for haemophilia drug

* Says the European Commission has granted marketing authorisation for Refixia for treatment of adolescents and adults with haemophilia B

06 Jun 2017

BRIEF-Innate Pharma acquires anti-c5ar from Novo Nordisk A/S

* Innate Pharma acquires anti-c5ar, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

03 Jun 2017

BRIEF-Innate Pharma acquires anti-C5aR from Novo Nordisk

* Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

03 Jun 2017

Novo Nordisk looks to shore up European market share

COPENHAGEN, June 2 Novo Nordisk, the world's biggest maker of diabetes drugs, will focus on growing volumes rather than price in its key European market where it has lost ground to competitors in recent years, a senior executive said on Friday.

02 Jun 2017

Novo Nordisk submits U.S. application for Tresiba label update

* Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba label

29 May 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €87.87 --
Eli Lilly and Co (LLY.N) $83.89 -0.42

Earnings vs. Estimates